Oricell Therapeutics Holdings Limited Files for IPO Following $70M Series C1 Financing to Advance Dual-Target In Vivo CAR-T Pipeline

Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.

PharmaCircleMonitoring Shows: Oricell Therapeutics Holdings Limited (hereinafter referred to as "Oricell" or "the Company"), from Zhangjiang, Shanghai, has completed a US$70 million Series C1 financing round. This round was led by Beijing Medical and Health Industry Investment Fund, Qiming Venture Partners, and a globally leading healthcare fund, with participation from QIA (Qatar Sovereign Fund), NGS (Australian Pension Fund), Yizhuang Guotou, Lich宸, Ruifeng, and others.

As an innovative pioneer in the field of cell therapy drugs, Qrigincell Therapeutics has always been committed to developing CAR-T cell therapies with global clinical value, and has generated proof-of-concept (POC) clinical data from multiple pipelines. Oricell relies on its self-innovated Ori^®Ab Antibody Screening and Engineering Platform, Ori^®The Armoring structural platform and OnGo(Fast)CMC process expertise enable a differentiated pipeline to occupy the global CAR-T technology high ground.

Ori-C101 by Qrigincell Therapeutics is a targetedGPC3-targeted Autologous CAR-T Therapy for Advanced Hepatocellular Carcinoma (HCC), has completed the Phase I investigator-initiated clinical study and registered Phase I clinical trial, and is about to launch the pivotal Phase II clinical trial. The clinical data read so far demonstrate excellent efficacy and safety, and have been presented multiple times at top international academic conferences such as ASCO. This product is expected to become the world's first approved CAR-T drug for hepatocellular carcinoma.

At the same time, Qrigincell Therapeutics' full platform is giving rise to multiple next-generation multi-target and multi-mechanism CAR-T products. Its innovative secretory CAR-T, OriC902, has achieved breakthrough efficacy in end-stage solid tumor patients; the company's self-developedDual-target in vivo CAR-T ProductionThe product has initiated exploratory clinical research, verifying the technical potential of "off-the-shelf CAR-T" – generating CAR-T cells directly within the patient's body, significantly enhancing the accessibility of cellular therapies.

Other layout targets includeGPRC5D,BCMA，CDH17Etc.

---